Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.

Growth Factor Receptor ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial

Cancer ◽

10.1002/cncr.30143 ◽

2016 ◽

Vol 122 (19) ◽

pp. 3032-3040 ◽

Cited By ~ 11

Author(s):

Florence Lerebours ◽

Sofia Rivera ◽

Marie-Ange Mouret-Reynier ◽

Severine Alran ◽

Laurence Venat-Bouvet ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

Phase 2 ◽

Breast Cancer Patients ◽

Postmenopausal Estrogen ◽

Epidermal Growth ◽

Randomized Phase 2

Abstract PD1-01: Open-label, randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor-2-negative (HER2-) advanced or metastatic breast cancer (MBC) that previously progressed during or after aromatase inhibitor therapy (NCT02756364)

10.1158/1538-7445.sabcs20-pd1-01 ◽

2021 ◽

Author(s):

José Á García-Saenz ◽

Noelia Martínez Jáñez ◽

Miguel Martin ◽

Ainhara Lahuerta Martínez ◽

Santiago González-Santiago ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Aromatase Inhibitor Therapy ◽

Phase 2 Study ◽

Epidermal Growth ◽

Randomized Phase 2

PO56 BOLERO-4: A PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF FIRST-LINE EVEROLIMUS (EVE) IN COMBINATION WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS (PTS) WITH ESTROGEN RECEPTOR–POSITIVE (ER+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HER2–) METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER (BC)

The Breast ◽

10.1016/s0960-9776(15)30068-0 ◽

2015 ◽

Vol 24 ◽

pp. S41

Author(s):

Thomas Bachelot ◽

Cristian Villanueva ◽

Melanie Royce ◽

Marc Debled ◽

Felipe Melo Cruz ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Growth Factor Receptor ◽

Phase 2 ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (BC)

Annals of Oncology ◽

10.1093/annonc/mdw365.01 ◽

2016 ◽

Vol 27 ◽

pp. vi68 ◽

Cited By ~ 5

Author(s):

M. Royce ◽

C. Villanueva ◽

M. Ozguroglu ◽

T. Bachelot ◽

S. Azevedo ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

Current Medical Research and Opinion ◽

10.1185/03007995.2016.1157060 ◽

2016 ◽

Vol 32 (5) ◽

pp. 959-965 ◽

Cited By ~ 11

Author(s):

T. Bell ◽

J.P. Crown ◽

I. Lang ◽

H. Bhattacharyya ◽

G. Zanotti ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

Daily Activities ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells

Molecular Medicine Reports ◽

10.3892/mmr.2018.8580 ◽

2018 ◽

Cited By ~ 1

Author(s):

Seung Taek Lim ◽

Ye Won Jeon ◽

Hongki Gwak ◽

Se Young Kim ◽

Young Jin Suh

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Breast Cancer Cells ◽

Growth Factor Receptor ◽

Anticancer Effects ◽

Epidermal Growth ◽

Positive Breast Cancer

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05125-4 ◽

2019 ◽

Vol 174 (3) ◽

pp. 719-729 ◽

Cited By ~ 56

Author(s):

H. S. Rugo ◽

R. S. Finn ◽

V. Diéras ◽

J. Ettl ◽

O. Lipatov ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.08.009 ◽

2020 ◽

Vol 20 (2) ◽

pp. e173-e180 ◽

Cited By ~ 3

Author(s):

Hope S. Rugo ◽

Richard S. Finn ◽

Karen Gelmon ◽

Anil A. Joy ◽

Nadia Harbeck ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Objective Response ◽

Growth Factor Receptor ◽

Progression Free Survival ◽

Survival Outcome ◽

Free Survival ◽

Abstract OT1-03-01: Phase 1/1b study of novel oral selective estrogen receptor degrader (SERD) LSZ102 in combination with alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with progression on endocrine therapy (ET)

10.1158/1538-7445.sabcs18-ot1-03-01 ◽

2019 ◽

Author(s):

G Curigliano ◽

S Cresta ◽

Y-S Yap ◽

D Juric ◽

FP Duhoux ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Phase 1 ◽

Growth Factor Receptor ◽

Abstract PD7-07: Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer

10.1158/1538-7445.sabcs19-pd7-07 ◽

2020 ◽

Author(s):

Virginia Kaklamani ◽

Aditya Bardia ◽

Sharon Wilks ◽

Amy Weise ◽

Donald Richards ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Final Analysis ◽

Phase 1 Study ◽